1. Home
  2. BCHT vs IXHL Comparison

BCHT vs IXHL Comparison

Compare BCHT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCHT

Birchtech Corp. Common Stock

N/A

Current Price

$1.62

Market Cap

55.0M

Sector

Industrials

ML Signal

N/A

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.65

Market Cap

45.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCHT
IXHL
Founded
N/A
2001
Country
United States
Australia
Employees
15
N/A
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
55.0M
45.0M
IPO Year
2026
2024

Fundamental Metrics

Financial Performance
Metric
BCHT
IXHL
Price
$1.62
$3.65
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
96.2K
460.8K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
$13.42
N/A
Revenue Next Year
$61.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$0.11
52 Week High
$2.45
$6.39

Technical Indicators

Market Signals
Indicator
BCHT
IXHL
Relative Strength Index (RSI) 30.60 60.88
Support Level N/A $0.34
Resistance Level $2.33 $3.68
Average True Range (ATR) 0.18 0.30
MACD -0.01 0.03
Stochastic Oscillator 7.06 86.49

Price Performance

Historical Comparison
BCHT
IXHL

About BCHT Birchtech Corp. Common Stock

Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: